Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
MedComm is Scopus-indexed (Q1, CiteScore 12.5), WoS ESCI, DOAJ. It is covered by India's One Nation One Subscription scheme, which pays the article processing charge for authors at eligible institutions. Published by John Wiley and Sons Inc.
Checked against the index lists dated .
ISSN 2688-2663Verify ISSN ↗
Publisher: John Wiley and Sons Inc
Cost to publish: APC covered for authors at ONOS-subscribed Indian institutions
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Genetics (clinical) | 5 / 100 | 95th | Q1 |
| Genetics | 21 / 357 | 94th | Q1 |
| Drug Discovery | 11 / 161 | 93rd | Q1 |
| Biochemistry (medical) | 7 / 78 | 91st | Q1 |
| Oncology | 38 / 428 | 91st | Q1 |
| Immunology and Allergy | 29 / 234 | 87th | Q1 |
| Cell Biology | 40 / 289 | 86th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription)
Yes — actively indexed in Scopus, coverage 2020–present, best quartile Q1, CiteScore 12.5.
MedComm is Q1 in Genetics (clinical) (rank 5 of 100), Q1 in Genetics (rank 21 of 357) and Q1 in Drug Discovery (rank 11 of 161), by CiteScore 2025. It is ranked in 7 subject areas in all.
MedComm is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 12.5, which places it in quartile Q1 at the 95th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.930, quartile Q1, with an H-index of 57.
For authors at Indian institutions covered by One Nation One Subscription (ONOS), the article processing charge is paid by the scheme. The publisher lists an article processing charge of about US$3,500 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
MedComm is published by John Wiley and Sons Inc. Its ISSN is 2688-2663.
Yes. ONOS also covers its article processing charge for authors at eligible institutions.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
MedComm has an h-index of 80 and a 2-year mean of 10.7 citations per paper (OpenAlex). Its Scopus CiteScore is 12.5, quartile Q1. On 2-year citations it ranks #3 of 99 Scopus journals in Genetics (clinical).
MedComm published 533 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2026), authors are most often from China (79.5%), United States (3.7%) and Italy (2.3%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (1.1 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.